Another strong quarter for sales revenues with 19.5 % growth, ending at MNOK
202.0 (MNOK 169.1). Record sales revenue for the first half with 15.1 % growth,
ending at MNOK 403.7 (MNOK 350.6).
Currency neutral sales of own products were up 33.6 % for the quarter and 31.8 %
for the first half.
Strong currency neutral growth in all regions for the quarter; AMERICAS up 46.3
%, APAC up 22.4 % and EMEA up 19.4%.
Third-party distributor sales in Scandinavia decreased 7 % in the quarter and
19.9 % in the first half.
Operating profit (EBIT) grew by 20.6 % for the quarter and ended at MNOK 65.3,
resulting in 32.3 % EBIT margin MNOK 54.1, 32.0 % margin). First half operating
profit grew 8.0 % ending at a record MNOK 122.4, and 30.3 % EBIT margin (MNOK
113.3, 32.3 % margin).
The share of recurring sales remained high and ended at 67.0 % for the first
half (66.8 % for the same period last year).
Medistim announced the establishment of a direct sales operation in Japan,
effective from March 16, 2026.
Solid cash position at quarter end with MNOK 100.2 after paying a dividend of
NOK 8.00 per share (NOK 6.0), total MNOK 146.3 in May (MNOK 109.4). No
interest-bearing bank loans.
The Board will propose that the General Meeting authorize the distribution of
quarterly dividends.
the distribution of\
quarterly dividends.\